Updated hourlyHourly refreshWed, Oct 28, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Healthcare
M-M-R II Market M-M-R II Market Report M-M-R II Market Share The Business Research Company’s M-M-R II Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 28, 2026 / EINPresswire.com / -- The global M-M-R II market is experiencing steady growth, supported by strong scientific immunization frameworks and consistent public health commitments. This vacci
Oct 28 · 00:30·EIN Presswire
Healthcare · Biotech & pharma
Longevity BioTech Market Longevity BioTech Market Report Longevity BioTech Market Analysis The Business Research Company’s Longevity BioTech Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 28, 2026 / EINPresswire.com / -- The longevity biotechnology sector is gaining momentum as innovations in anti-aging therapies and regenerative medicine draw t
Oct 28 · 00:30·EIN Presswire
Healthcare · Biotech & pharma
BEIJING, Oct. 27, 2026 -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that latest data of orelabrutinib, its novel BTK inhibitor, were presented at the European Society for Medical Oncology (ESMO) Congress 2026.
Oct 28 · 00:30·GlobeNewswire
SaaS · Healthcare
Wednesday 28 October, 2026
Aachen, Germany, 28 October 2026 –
The trial (n=409) showed that Qutenza®
“Post-surgical neuropathic pain can be difficult to manage with current treatment options, and there is an urgent need for patient-centred, effective solutions. The RISE trial provides encouraging evidence that Qutenza® can deliver clinically meaningful and sustained pain reduction for up to 42 weeks, having shown a greater reduction in average pain intensity than the control,” said Prof. Patrice Forget, MD, PhD, FFPMRCA, Clinical Chair (full professor) in Anaesthesia, University of Aberdeen, and Honorary Consultant, NHS Grampian, Aberdeen, UK. “As IASP shines a global spotlight on neuropathic pain at this year's congress, findings such as these are important to help improve outcomes for patients and reduce the burden of pain on families and healthcare systems.”
“Post-surgical neuropathic pain has been relatively understudied and continues to go under-recognised in clinical practice,” said Uli Brödl, Chief Scientific Officer, Grünenthal. “These results build on the robust body of evidence for Qutenza® and reinforce its potential to provide meaningful, long-lasting pain relief for people living with pain.”
Post-surgical neuropathic pain is a poorly recognised potential complication of surgery that can result in devastating outcomes. It affects millions of patients every year, with pain lasting for months or years post-procedure.1 It can also have a significant mental health impact, with patients reporting feeling extremely depressed or anxious, and having problems with daily activities.[4]
Qutenza® is already approved in Europe for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain.[5] It is also approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults.[6]
About the RISE trial2,3
The RISE (AV-001) trial is a Phase III multi-centre, randomised, double-blind, parallel-group trial to confirm the efficacy and safety of Qutenza 179mg cutaneous patch versus a low-dose capsaicin control patch in people with moderate to severe post-surgical neuropathic pain.
It included eligible adults with a 24-hour average pain intensity (API) score of 4 or more, a pain duration of 6 to 60 months after index surgery and a DN4 (Douleur Neuropathique 4) Interview score of 3 or more.
Participants were randomly assigned to receive treatment with either a 60-minute Qutenza patch (8%) or a low-dose capsaicin control patch (0.04%).
The trial had two primary endpoints:
Change in 24-hour API from baseline to the average score of the entire period between Week 2 and Week 12. Change in 24-hour API from baseline to the average score at Week 12.
The primary sponsor of the trial is Averitas Pharma, Inc., Grünenthal’s U.S. subsidiary.
About post-surgical neuropathic pain
The signs and symptoms of peri- and post-surgical pain can vary based on the person and the severity of the injury caused in surgery. Reported symptoms include pain caused by stimuli that are normally painless (allodynia), abnormally increased sensitivity to pain (hyperalgesia), tingling, numbness, phantom pain and scar pain.[8],[9],[10]
About Qutenza®
Qutenza®
Qutenza®
About Grünenthal
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2025, Grünenthal employed around 4,100 people and achieved revenues of €1.8 billion.
Follow us on LinkedIn
For further information, please contact:
Matt Crabb, Head of Global Communications (Interim) at Grünenthal
matt.crabb@grunenthal.com
###
References
[1] Gregory P & Settles K. Pract Pain Manag. 2013;13(9):1–6.
[2] Wallace M et al. Efficacy of high-concentration capsaicin patch in post-surgical neuropathic pain (RISE). Presented at the International Association for the Study of Pain World Congress 2026.
[3] Wallace M et al. Safety and tolerability of high-concentration capsaicin patch in post-surgical neuropathic pain (RISE). Presented at the International Association for the Study of Pain World Congress 2026.
[4] Santos MP, Lemos F, Gomes J, Romao JM, Veiga D. Br J Pain 2024;18(1):42–56.
[5] European Medicines Agency. Qutenza 179 mg cutaneous patch SmPC. Available at: https://www.medicines.org.uk/emc/product/573/smpc
[6] US Food and Drug Administration. Qutenza® Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022395s019lbl.pdf
[7]
[8] Werner MU & Kongsgaard UE. Br J Anaesth. 2014;113(1):1–4.
[9] Macrae WA. Br J Anaesth. 2008;101:77–86.
[10] Searle RD & Simpson KH. Contin Educ Anaesth Crit Care Pain. 2010;10:12–14.
Oct 28 · 00:00·Pressat
Healthcare
Badger Bob's Services was recognized as a top-rated AC repair company in Sarasota for 2026, highlighting its commitment to reliable HVAC services, quality repairs, and customer satisfaction.
Oct 28 · 00:00·1888 Press Release
Healthcare · Education
Options for chronic knee pain Patient education focuses on knee osteoarthritis, available treatment approaches, and considerations involved in deciding whether surgery is appropriate. FAIRPORT, NY, UNITED STATES, October 27, 2026 / EINPresswire.com / -- Rochester Arthritis & Joint Pain Center , serving patients in Rochester, New York, is providing information to help individuals with chronic knee pain better understa
Oct 28 · 00:00·EIN Presswire
Healthcare · Biotech & pharma
HANGZHOU, China, SHANGHAI and BOSTON, Oct. 27, 2026 -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase...
Oct 28 · 00:00·PR Newswire
Healthcare
Dr. Mohana Rao Patibandla presenting his neurosurgical work at SBNS100, celebrating 100 years of British neurosurgery, at the QEII Centre, London, October 2026. Dr. Mohana Rao Patibandla, Founder and Chief Neurosurgeon of Dr. Rao’s Hospital, participating in the Society of British Neurological Surgeons’ centenary meeting in London. Photo credit: Special Arrangement / The Hindu. From wheelchair-bound to walking again:
Oct 28 · 00:00·EIN Presswire
Healthcare · Medical devices
Dental treatment room with chair and city view window at Smile Dental Care in Miami Dentist in mask examining an older patient's teeth in treatment chair at Smile Dental Care Smile Dental Care in Miami, FL SMILE DENTAL CARE — Dental.me Verified, Score 95 The Miami practice pairs comprehensive family dentistry — from implants to emergency care — with Saturday hours and a whole-patient philosophy. A healthy smile goes
Oct 27 · 23:22·EIN Presswire
Finance · Healthcare
NEW YORK, Oct. 27, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026...
Oct 27 · 23:13·PR Newswire
Healthcare · Biotech & pharma
Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET
Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET
Oct 27 · 22:00·GlobeNewswire
Finance · Healthcare
HENDERSON, Nev., October 27, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today rep
Oct 27 · 22:00·Business Wire